CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -47.42% | -58.80% | -103.80% | -75.99% | -77.61% |
| Total Depreciation and Amortization | -0.52% | 1.14% | -3.40% | -2.75% | -2.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.99% | 202.87% | 159.54% | 173.65% | 2.23% |
| Change in Net Operating Assets | 158.76% | -54.00% | 206.60% | -137.91% | 103.14% |
| Cash from Operations | -30.51% | -141.65% | -60.20% | -166.73% | -92.24% |
| Capital Expenditure | 12.55% | 51.92% | 72.70% | 81.42% | 80.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -109.69% | 88.91% | 108.05% | 97.36% | -221.01% |
| Cash from Investing | -108.85% | 88.66% | 107.87% | 96.99% | -227.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,036.25% | 28.15% | -7.91% | -88.64% | -89.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,649.46% | 28.33% | -7.78% | -88.62% | -89.91% |
| Foreign Exchange rate Adjustments | -29.03% | 552.38% | -94.49% | 2,625.00% | 3.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.09% | 154.00% | 120.11% | -838.26% | -230.16% |